{"id":403528,"date":"2020-12-21T08:03:11","date_gmt":"2020-12-21T13:03:11","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=403528"},"modified":"2020-12-21T08:03:11","modified_gmt":"2020-12-21T13:03:11","slug":"algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/","title":{"rendered":"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">VANCOUVER, British Columbia, Dec.  21, 2020  (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d), a clinical stage pharmaceutical development company, is pleased to announce that Algernon\u2019s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company\u2019s interim data report for part 2b of the Company\u2019s Phase 2b\/3 clinical study of Ifenprodil for COVID-19 on an upcoming Streetsmart<strong><em> Live!<\/em><\/strong> webcast. They will be joined by Dr. Mark Swaim, founder of BIOPUB and Steve Palmer,\u00a0President and CEO of AlphaNorth Asset Management, as they also discuss upcoming catalysts and events.<\/p>\n<p align=\"justify\">The<em>\u00a0<\/em>Streetsmart <strong><em>Live! <\/em><\/strong>webcast will be held Monday December 21, 2020 hosted at noon EST. The Company invites interested shareholders, investors, members of the media and the public to listen to the interview free of charge.<\/p>\n<p>Please click the link below to join the webinar:<\/p>\n<p><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eqRLSZVNY9c3K9vibju_F_p84JIkiLkLHaJp5uQtRI1Co410mDXzCEHzJhRVkBlsMHq5rX8SREBiYgf5d1h_dpoaeKOl7hGdQJlOl0x4bkSwzqyN3uSaCDGJVX9N9bxt-qyzgYsyA8M1NsvOGrdjs8H038ZmTpm8fqGoSeMr-QiwCgav1GQ01DCRehiz3Wr658QrboUltfhANKKDlgdp1qrt1TpvDrMUEE08NT-d6fDvkekIxoyiMuC1pNCwzZRE\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/www.streetwisereports.com\/events\/register\/?event_id=69&amp;utm_source=AGN_PR<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>About Streetwise Reports<\/strong>\n      <\/p>\n<p align=\"justify\">Since 2001, Streetwise Reports has been the place where investors go to read about promising investment ideas straight from leading industry experts, analysts, newsletter writers and money managers.<\/p>\n<p align=\"justify\">\n        <strong>About Algernon Pharmaceuticals Inc.\u00a0<\/strong>\n      <\/p>\n<p align=\"justify\">Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.<\/p>\n<p align=\"justify\">Algernon has filed new intellectual property rights globally for NP-120 (Ifenprodil) for the treatment of respiratory diseases and is working to develop a proprietary injectable and slow release formulation.<\/p>\n<p align=\"justify\">\n        <strong>CONTACT INFORMATION<\/strong>\n      <\/p>\n<p>Christopher J. Moreau<br \/>CEO<br \/>Algernon Pharmaceuticals Inc.<br \/>604.398.4175 ext 701\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gg8ETNGn8__2eqjDPG_k6pnGM0O8WRp_vqpPSUuJnF0NUW2Ix5diF_5VOCaQ2gEYnG26AsNTQus_CTm3hRhXbR46YB3TNjOfqswXNDJYXXokjeIOmsiBZoN5lP_PgIFT\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@algernonpharmaceuticals.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ghyQZCZjTs43Z_Q9qJGHGZPggDFNK7D1uZDzwLO34MROLTjlM5UkaaJvKQpewS42yI0Uj6YvwjgW2oDl1gsD7Q==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rVaCh4iBW6BRrmIOc5eEVLB-5q-qQ9kQDZSUCbkmY0ImdrPQvLE9bcnnx5u-GKFcUUKlmHX9fhyTQo5w2IOxEdZuLP7NkSGbkziAGJucyGCrSCRC6Hc_3BISVm8_w08l\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">investors@algernonpharmaceuticals<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QTDcBlVPuUcHqdtKxzoq34eJu_Yp2vI0tKDbE69TgPEQWd2M_K2smJV8VGrDC0zDNJrWkSS8YD_KhYGR0VsYM-qBqQDdNxf6rCZx8HcYydA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">.com<br \/><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kt24OknaSKW-mEg-zI56yqHyKWRR0c29LHH_oxxZTyPZx2ti3CsIvV1l-P1SWAoDYHy8aGirlc4mY-apkeeCnK-qCtZ4GxMxxX7vsLx5fqnddK4oslGBl3sT5yocwzQ8\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.algernonpharmaceuticals.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <em>Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. <\/em><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">\n        <em>CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as \u201cwill\u201d, \u201cmay\u201d, \u201cshould\u201d, \u201canticipate\u201d, \u201cexpects\u201d and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company\u2019s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.<\/em>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/ef88ac03-5621-46da-b4fc-f8baddab4547\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>VANCOUVER, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d), a clinical stage pharmaceutical development company, is pleased to announce that Algernon\u2019s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company\u2019s interim data report for part 2b of the Company\u2019s Phase 2b\/3 clinical study of Ifenprodil for COVID-19 on an upcoming Streetsmart Live! webcast. They will be joined by Dr. Mark Swaim, founder of BIOPUB and Steve Palmer,\u00a0President and CEO of AlphaNorth Asset Management, as they also discuss upcoming catalysts and events. The\u00a0Streetsmart Live! webcast will be held Monday December 21, 2020 hosted at noon EST. The Company invites interested shareholders, investors, members of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-403528","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d), a clinical stage pharmaceutical development company, is pleased to announce that Algernon\u2019s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company\u2019s interim data report for part 2b of the Company\u2019s Phase 2b\/3 clinical study of Ifenprodil for COVID-19 on an upcoming Streetsmart Live! webcast. They will be joined by Dr. Mark Swaim, founder of BIOPUB and Steve Palmer,\u00a0President and CEO of AlphaNorth Asset Management, as they also discuss upcoming catalysts and events. The\u00a0Streetsmart Live! webcast will be held Monday December 21, 2020 hosted at noon EST. The Company invites interested shareholders, investors, members of &hellip; Continue reading &quot;Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-21T13:03:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast\",\"datePublished\":\"2020-12-21T13:03:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/\"},\"wordCount\":646,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/\",\"name\":\"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=\",\"datePublished\":\"2020-12-21T13:03:11+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/","og_locale":"en_US","og_type":"article","og_title":"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast - Market Newsdesk","og_description":"VANCOUVER, British Columbia, Dec. 21, 2020 (GLOBE NEWSWIRE) &#8212; Algernon Pharmaceuticals Inc.\u00a0(CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the \u201cCompany\u201d or \u201cAlgernon\u201d), a clinical stage pharmaceutical development company, is pleased to announce that Algernon\u2019s CEO Christopher J. Moreau and CSO Dr. Mark Williams, will be discussing the Company\u2019s interim data report for part 2b of the Company\u2019s Phase 2b\/3 clinical study of Ifenprodil for COVID-19 on an upcoming Streetsmart Live! webcast. They will be joined by Dr. Mark Swaim, founder of BIOPUB and Steve Palmer,\u00a0President and CEO of AlphaNorth Asset Management, as they also discuss upcoming catalysts and events. The\u00a0Streetsmart Live! webcast will be held Monday December 21, 2020 hosted at noon EST. The Company invites interested shareholders, investors, members of &hellip; Continue reading \"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-21T13:03:11+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast","datePublished":"2020-12-21T13:03:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/"},"wordCount":646,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/","name":"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=","datePublished":"2020-12-21T13:03:11+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExNTY5MCMzODkwNTQ1IzIwOTIzNjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/algernon-ceo-and-cso-to-discuss-covid-19-study-interim-data-results-featured-on-streetsmart-live-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Algernon CEO and CSO to Discuss COVID-19 Study Interim Data Results Featured on Streetsmart Live! Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403528","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=403528"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/403528\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=403528"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=403528"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=403528"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}